Verrica Pharmaceuticals annual debt-to-equity ratio
2019
2020
2021
2022
2023
2025
Verrica Pharmaceuticals Debt-to-Equity Ratio Growth & History (VRCA)
Verrica Pharmaceuticals's debt-to-equity ratio was 0.07 for fiscal 2025.
View full Verrica Pharmaceuticals company overviewVerrica Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.07 | — | — |
| 2023 | 2023-12-31 | 2.30 | 2.26 | +5941.12% |
| 2022 | 2022-12-31 | 0.04 | −1.29 | −97.14% |
| 2021 | 2021-12-31 | 1.33 | 0.20 | +18.04% |
| 2020 | 2020-12-31 | 1.13 | 1.13 | +38906.69% |
| 2019 | 2019-12-31 | 0.00 | — | — |
Verrica Pharmaceuticals quarterly debt-to-equity ratio
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.42 | — | — |
| Q1 2026 | 2026-03-31 | 0.09 | — | — |
| Q4 2025 | 2025-12-31 | 0.07 | — | — |
| Q1 2024 | 2024-03-31 | 30.80 | 30.78 | +137445.01% |
| Q4 2023 | 2023-12-31 | 2.30 | 2.26 | +5941.12% |
| Q3 2023 | 2023-09-30 | 1.04 | 1.00 | +2807.10% |
| Q2 2023 | 2023-06-30 | 0.02 | −2.67 | −99.08% |
| Q1 2023 | 2023-03-31 | 0.02 | −1.69 | −98.69% |
| Q4 2022 | 2022-12-31 | 0.04 | −1.29 | −97.14% |
| Q3 2022 | 2022-09-30 | 0.04 | −1.02 | −96.62% |
| Q2 2022 | 2022-06-30 | 2.69 | 1.87 | +227.80% |
| Q1 2022 | 2022-03-31 | 1.71 | 1.02 | +148.54% |
| Q4 2021 | 2021-12-31 | 1.33 | 0.20 | +18.04% |
| Q3 2021 | 2021-09-30 | 1.06 | 0.11 | +11.86% |
| Q2 2021 | 2021-06-30 | 0.82 | 0.10 | +14.24% |
| Q1 2021 | 2021-03-31 | 0.69 | 0.08 | +12.61% |
| Q4 2020 | 2020-12-31 | 1.13 | 1.13 | +38906.69% |
| Q3 2020 | 2020-09-30 | 0.94 | 0.94 | +30917.82% |
| Q2 2020 | 2020-06-30 | 0.72 | 0.72 | +22178.28% |
| Q1 2020 | 2020-03-31 | 0.61 | 0.61 | +18090.88% |
| Q4 2019 | 2019-12-31 | 0.00 | — | — |
| Q3 2019 | 2019-09-30 | 0.00 | — | — |
| Q2 2019 | 2019-06-30 | 0.00 | — | — |
| Q1 2019 | 2019-03-31 | 0.00 | — | — |
Verrica Pharmaceuticals debt-to-equity ratio trends
Over the last five fiscal years, Verrica Pharmaceuticals's debt-to-equity ratio decreased from 1.13 to 0.07, a change of −1.06. The latest reported quarter, Q2 2026, shows 0.42.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Verrica Pharmaceuticals source filings ↗